Archives: Agenda

China has become a major source of biopharma innovation, clinical assets, and evidence. For global sponsors, the practical question is where China can add value to a program, what limitations need to be considered, and what it takes for China-generated evidence to support development decisions in other regions.

Drawing on recent discussions with biotech and pharma leaders in China and the United States, this session will offer a sponsor-side framework for:

• Understanding the sources of China’s development speed and how much the potential advantage depends on the asset, indication and development stage
• Determining where China can add value in a global program: as a location for clinical development, a source of assets and evidence, or a strategic partner
• Examining the factors that shape EMA and FDA assessments of China-generated evidence, including patient population, dose and exposure, standard of care, comparators, treatment sequencing and data integrity
• Choosing the next development step: using the existing package, adding a focused bridging component, or designing a multiregional clinical trial
• Defining the clinical, CMC, quality, and data governance requirements for a cross-regional program

• Translating development strategy into protocols that are scientifically robust, operationally feasible and easier for sites to deliver
• Reducing protocol complexity through earlier input from medical, operational, regulatory and site stakeholders
• Applying country and site intelligence to accelerate start-up, strengthen recruitment planning and maintain momentum during execution
• Considering how AI can accelerate delivery across the clinical development lifecycle

Taking control of development to accelerate proof of concept and maximize value.

• Is your strategy accelerating development—or delaying it? Align regulatory and operational planning from day one
• Your sites can make or break your timeline
• Case study: Spend less. Move faster. Prove more

• The real cost of “free” software and the security gaps it creates
• How technical debt in open-source stacks becomes a growing risk for financial institutions
• Why traditional “shift left” approaches are no longer enough
• What a secure-by-default model looks like and what organisations should expect from their tools and teams

As financial services firms continue to digitise, their exposure now stretches far beyond the traditional perimeter. From the dark web to domain impersonation and unpatched vulnerabilities, risks can emerge anywhere your brand or data appear online.

This session explores how organisations can harness diverse intelligence sources – including the dark web – to uncover hidden risks and strengthen their digital resilience. Through real-world examples, we’ll show how Digital Risk Protection (DRP) turns threat data into clear, actionable insight that helps financial institutions stay ahead of attackers

The financial services market has driven major security improvements through frameworks such as CBEST and TIBER, with its behaviour helping raise standards across other sectors. But does confidence still outpace reality? This session explores the blind spots that remain, including fragile supply chains, hidden attack paths, and vendor risks, while challenging what resilience and true assurance mean in complex, real-world environments

• Innovative KYA (Know Your Asset) platform and how does it work
• AI algorithms specialized for the leasing domain
• How to save on risk provisions with KYA Risk
• How to produce accurate sustainability reporting with KYA ESG